Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hannah Fields

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|August 22, 2022
Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killingValentina Ferrari, Alison Tarke, Hannah Fields, et al.
Cytotherapy|December 6, 2020
Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndromeTiffany N Tanaka, Valentina Ferrari, Alison Tarke, et al.
Cytotherapy|December 2, 2020
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burdenValentina Ferrari, Alison Tarke, Hannah Fields, et al.
Immunity|August 5, 2022
DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophagesIsidoro Cobo, Tiffany N Tanaka, Kailash Chandra Mangalhara, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|August 22, 2022
Tumor-specific T cell-mediated upregulation of PD-L1 in myelodysplastic syndrome cells does not affect T-cell killingValentina Ferrari, Alison Tarke, Hannah Fields, et al.
Cytotherapy|December 6, 2020
Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndromeTiffany N Tanaka, Valentina Ferrari, Alison Tarke, et al.
Cytotherapy|December 2, 2020
In vitro induction of neoantigen-specific T cells in myelodysplastic syndrome, a disease with low mutational burdenValentina Ferrari, Alison Tarke, Hannah Fields, et al.
Immunity|August 5, 2022
DNA methyltransferase 3 alpha and TET methylcytosine dioxygenase 2 restrain mitochondrial DNA-mediated interferon signaling in macrophagesIsidoro Cobo, Tiffany N Tanaka, Kailash Chandra Mangalhara, et al.
Pageof 1